Oric Pharmaceuticals, Inc. (ORIC) · Oct 23, 2026 · Other events

ORIC enozertinib data clears Phase 3 path with strong CNS responses

Phase 3 advancement — 84% confirmed systemic ORR; 67% BICR CNS ORR; Redwood-1 planned for 1H 2027

ORIC’s enozertinib clinical update shows deep systemic and brain responses in EGFR atypical lung cancer, supporting a global Phase 3 launch in 2027.

ORIC is a late-stage oncology company advancing two lead programs: rinzimetostat is already in Phase 3, while enozertinib is being developed as a CNS-active targeted therapy for EGFR atypical and exon 20 non-small-cell lung cancer. Before this filing, the company had already signaled an enozertinib clinical update in the second half of 2026 and a possible registrational path, with roughly $388 million of cash and investments expected to fund operations into the second half of 2028.

The clinical signal is materially stronger than a routine update. In first-line EGFR atypical NSCLC, enozertinib produced an 84% confirmed systemic response rate in 25 response-evaluable patients, while blinded central review confirmed an 80% rate. Its central-nervous-system activity was also substantial: 70% confirmed intracranial response by investigator assessment and 67% by the more stringent BICR RANO-BM assessment, including six complete responses. The result is notable because 65% of the 26-patient safety population had baseline brain metastases, including 46% with previously untreated brain metastases. 〔0〕

MeasureEnozertinib resultComparison / context
Confirmed systemic ORR84% investigator; 80% BICRCompetitor programs shown at roughly 50%–68% (Clinical data benchmarks)
Confirmed intracranial ORR70% investigator; 67% BICR RANO-BMCompetitor programs shown at roughly 29%–40% (Clinical data benchmarks)
Six-month landmark PFS88%Comparator benchmarks shown at roughly 65%–75% (Clinical data benchmarks)
Treatment discontinuations due to adverse events0%No treatment-related discontinuations (Safety and tolerability profile)
Baseline CNS metastases65% of N=26Nearly half had untreated brain metastases (Demographics and baseline characteristics)

The filing converts promising Phase 1b data into a credible registrational plan. ORIC says its End-of-Phase 1 FDA interactions aligned on the recommended Phase 3 dose, endpoints, statistical methodology, patient population and control arm, supporting a randomized Redwood-1 study against osimertinib or afatinib. This is the key business change: the program moves from “potentially registrational” to an FDA-aligned Phase 3 design with a stated launch window.

The main qualification is maturity, not an obvious efficacy problem. Follow-up was only 10.5 months, median progression-free survival and duration of response were not yet mature, and the dataset is small and single-arm. The filing reports that the median time on treatment had not been reached and that most patients remained on therapy. 〔1〕 Safety also looks manageable in this early dataset: adverse events were mainly Grade 1 or 2, no Grade 4 or 5 treatment-related adverse events occurred, and there were no treatment-related discontinuations. 〔2〕

Bottom line: This is a meaningful upgrade to enozertinib’s development story: unusually strong early systemic and CNS activity now supports a defined Phase 3 path. The evidence is still immature and based on a small cohort, but the filing advances the program rather than merely confirming an already-scheduled milestone.

What to watch next

Redwood-1 Phase 3 initiation, 1H 2027

Original filing on SEC EDGAR

ORIC enozertinib data clears Phase 3 path with strong CNS responses | ORIC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.